Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LuxR-type quorum sensing transcriptional regulators are a major family of bacterial proteins that coordinate collective behavior through cell-to-cell communication (Papenfort & Bassler, 2016). These regulators typically consist of an N-terminal ligand-binding domain (LBD) and a C-terminal DNA-binding domain (DBD) (UniProt). They function by sensing small signaling molecules, most commonly N-acyl homoserine lactones (AHLs), which accumulate as bacterial population density increases (Chen et al., 2011). Upon binding their specific AHL ligand, LuxR-type proteins often undergo dimerization and bind to "lux-box" sequences in the promoter regions of target genes (Defoirdt, 2018). This binding triggers the expression of various factors, including virulence enzymes, biofilm components, and metabolic pathways (PubMed). Because these regulators control the pathogenicity of significant human pathogens like Pseudomonas aeruginosa, they are highly attractive targets for anti-virulence therapies (StatPearls). Inhibiting these proteins aims to "disarm" the bacteria rather than kill them, which may reduce the selective pressure for antibiotic resistance (Nature Reviews Microbiology). Current drug discovery efforts focus on small-molecule antagonists, such as AHL analogs and natural products like baicalein, which competitively inhibit the LBD (PubChem). These inhibitors can prevent the functional folding or DNA-binding activity of the regulator, effectively silencing the bacteria's communication (Journal of Bacteriology). Therapeutic challenges include achieving sufficient penetration into established biofilms and ensuring specificity to avoid disrupting beneficial host microbiota (Microbiology and Molecular Biology Reviews).
Competitive inhibition of autoinducer binding to the ligand-binding domain, prevention of protein dimerization, or interference with DNA binding to suppress virulence gene expression.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LuxR-type quorum sensing transcriptional regulator (LuxR) (LuxR).